Meves Pharmaceuticals

About:

Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes.

Website: https://www.mevespharma.com

Description:

Meves Pharmaceuticals is developing nucleoside based therapies for mitochondrial DNA (mtDNA) depletion syndromes (MDS or MDDS), a category of severe genetic diseases. The initial focus is on therapy tailored specifically to treat patients with Thymidine Kinase 2 (TK2) deficiency, a discrete monogenic disorder associated with profound skeletal myopathy.